Non-small cell lung cancer · line 2 · Trastuzumab deruxtecan (DESTINY-Lung01/02) — HER2-mutant NSCLC 2L+

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-T-DXD-NSCLC`

ID	`IND-NSCLC-2L-HER2-MUT-T-DXD`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-NSCLC`
Sources	`SRC-DESTINY-BREAST03-CORTES-2022` `SRC-DESTINYLUNG01-LI-2022` `SRC-DESTINYLUNG02-GOTO-2023` `SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-NCCN-NSCLC-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Standard-track for HER2-mutant NSCLC 2L+. Drug physically available in UA (registered + reimbursed for breast); NSCLC indication funding is administrative gate, not import. HER2 amplification + overexpression in NSCLC are separate (rarer, less-validated) targets — different Indications.

Used By

Algorithms

ALGO-NSCLC-METASTATIC-2L - ALGO-NSCLC-METASTATIC-2L